ARAlistair Rogers

Alistair Rogers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alistair Rogers has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Manhire

    Departments of Urology, Radiology and

    1 shared publication
  • Antony Darné

    Department of Histopathology, Royal Victoria Infirmary, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, NE1 4LP, UK

    1 shared publication
  • David Rix

    Departments of Urology

    1 shared publication
  • James Glendinning

    Department of Urology, Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, UK

    1 shared publication
  • Jenny Koo Ng

    Department of Urology, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust

    1 shared publication
  • NaeemA Soomro

    Department of Urology, Freeman Hospital, NE7 7DN, UK

    1 shared publication

Latest Publications

  • Open Access

    Management of secondary pelviureteric junction obstruction

    by Alistair Rogers, Tahseen Hasan

    Pelviureteric junction obstruction (PUJO) of the kidney can lead to a number of different clinical manifestations, which often require surgical intervention. Although the success of pyeloplasty and endopyelotomy are good, there are still a number of patients who fail primary treatment and develop secondary PUJO. These treatment failures can be a challenging cohort to manage. This article aims to provide a comprehensive overview on the surgical options available to the urologist for managing secondary PUJO as well as providing some guidance on assessing factors that will influence management decisions.


  • The management of transitional cell carcinoma (TCC) in a European regional renal transplant population

    by Alistair Rogers, Jenny Koo Ng, James Glendinning, David Rix

    Study Type – Therapy (prospective cohort) Level of Evidence 2a What's known on the subject? and What does the study add? In the West, transitional cell carcinoma (TCC) in renal transplant patients is uncommon, but aggressive. Conversely, it appears to be frequent in the Far East, necessitating aggressive surgical approaches such as prophylactic nephroureterectomy. There are few European case series to date. TCC in the present population was predominantly low‐grade and superficial, with no progression in patients with those tumours. Endoscopic management was sufficient for most patients. The behaviour of TCC in the present population was much less aggressive than that described in the Far East. Altering immunosuppression regimes may have a role to play in managing bladder cancer in renal transplant patients. OBJECTIVE: To examine the clinical characteristics, management and long‐term outcomes of patients with transitional cell carcinoma (TCC) who also have had renal transplantation. PATIENTS AND METHODS: A retrospective case note review was performed for the 15‐year period 1995–2009. Searches from three different urological centres in the UK, using multiple sources, yielded 1647 patients with renal transplants, 12 of whom had TCC. Eight cases were identified who developed de novo TCC after transplantation (0.48%). Four patients had pre‐existing TCC who then had renal transplantation. The current literature was reviewed. RESULTS: In the eight de novo TCC cases, the bladder was the site in all with no upper tract TCC; seven were superficial (pTa/T1) and five were low grade (G1/2). The mean time to development of TCC after transplant was 5 years, with a mean follow‐up of 11 years. There was no progression in low‐grade superficial disease that was managed endoscopically. The 5‐ and 10‐year overall survival was 83% and 72%, respectively. In patients with pre‐existing TCC prophylactic bilateral nephroureterectomy before transplantation was performed once. There was progression of superficial disease whilst on immunosuppression in one patient. Sirolimus was used in patients with TCC and reports suggest this may have a role to play in modifying malignancy in this setting. The number of patients involved in studies particularly focusing on TCC in renal transplantation is small (136 patients), with 60% from China/Taiwan where there is a high incidence of upper tract TCC and high‐grade muscle‐invasive disease. CONCLUSIONS: Although this is one of the largest European case series of renal transplant patients with TCC, the numbers are small making clear conclusions difficult. The frequency of TCC in our renal transplant population is low, consistent with previous studies. However, contrary to prior studies, TCC after renal transplantation in this European population was predominantly superficial, low‐grade, non‐progressive and confined to the bladder. Altering immunosuppression regimes in patients with TCC may have a role to play, although further work is required to clarify and substantiate this.


  • Open Access

    Incidental metastatic endocrine tumor diagnosed at laparoscopic radical prostatectomy and bilateral lymph node dissection

    by Alistair George Rogers, Antony Darné, NaeemA Soomro

    The introduction and expansion of laparoscopic and robotic radical retropubic prostatectomy (LRRP and RRRP) for organ-confined prostate cancer have led to an increase in pelvic lymphadenectomy specimens. Extended lymph node dissection (eLND) involves removing nodes over the obturator fossa, external ileac vessels as well as the internal iliac and increases the number of nodes examined. This has the potential to increase incidental nonprostatic nodal pathology identified in prostatectomy specimens. For the first time in the current literature we report the incidental diagnosis of a metastatic small bowel endocrine tumor in a 69-year-old gentleman, made at the time of LRRP and bilateral lymph node dissection. This report suggests that the benefit of an extended lymph node dissection is not only to prostate cancer control and staging, but also to the possibility of diagnosing potentially treatable incidental disease. It is a possibility that both pathologists and urologists alike should be aware of.